On this page
What it is
A 4-amino-acid peptide (Lys-Glu-Asp-Gly) from the Khavinson short peptide series, in which each sequence is proposed to act on a specific tissue — here testicular. Epitalon is the best-known member of the same family.
How it is proposed to work
The programme's central hypothesis is that very short peptides can enter cells, reach the nucleus and interact with DNA in a sequence-specific way, modulating gene expression in the tissue each peptide is matched to. This is a strong and specific claim. It is also testable, and independent testing is what the literature most lacks.
Approved medical uses
None. Testagen has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
No adequate published human research. This absence is the reason for the evidence grade above — it is not a gap we can fill with animal data.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
- In vitro2011
Labelled testagen reaches HeLa cell nuclei; cell-free binding to DNA oligonucleotides
Finding. HeLa cells, a human cancer cell line, were incubated with fluorescein-labelled testagen (Lys-Glu-Asp-Gly), tested alongside labelled epithalon and pinealon. The authors report "marked fluorescence in cytoplasm, nucleus, and nucleolus". In separate cell-free fluorescence-quenching assays using the unlabelled ("intact") peptides, the Stern-Volmer quenching constants against labelled single- and double-stranded DNA oligonucleotides differed with peptide primary structure. The authors read this as sequence-specific binding to nucleic acids, and write that epithalon, testagen and pinealon "seem to preferentially bind with CAG-" containing sequences. The abstract reports only localisation and binding; it reports no functional, hormonal, reproductive or testicular outcome. The paper prints the sequence as "testagen, Lys-Glu-Asp-Gly".
Limitation. This comes from the originating programme: V.Kh. Khavinson is a co-author, so it is not an independent group. PubMed prints an affiliation only for the first author (Fedoreyeva: All Russia Research Institute of Agricultural Biotechnology, Russian Academy of Agricultural Sciences, Moscow) and none for Kireev, Khavinson or Vanyushin. Khavinson's connection to the St Petersburg programme is therefore established by his authorship elsewhere, not by an affiliation printed on this paper. We found no independent replication of the nuclear-uptake or DNA-binding result for this sequence. The one independent paper on KEDG we located (PMID 40807317, University of Craiova) is copper-corrosion chemistry and tests no biological claim. Fluorescence from a labelled peptide shows where the label went, and the abstract does not say whether the peptide remained intact inside the cell. The binding experiments were cell-free, so they do not show that binding occurs in cells. The abstract reports no measurement of gene activity; its statements about gene regulation are the authors' interpretation. HeLa is a cervical cancer line, not testicular tissue, so this says nothing about the tissue specificity the dossier attributes to the peptide. PubMed's 'Humans' index term reflects the human cell line; this is not human evidence. All of this is read from the abstract, not the full text.
Potential safety concerns
- CautionInsufficient
No systematic human safety dataset we could inspect. Very short peptides are often assumed benign on the basis of size alone, which is an assumption rather than a finding.
- CautionInsufficient
If the nuclear gene-expression mechanism is real, its long-term consequences would need study. If it is not real, the compound does nothing. Both possibilities argue for evidence before use, and neither has been resolved.
Known interactions and contraindication considerations
- Uncharacterised in accessible literature.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
Russian Federation Ministry of Health / Roszdravnadzor | Listed as of 11 Aug 2026 | Marketed in Russia, generally in a supplement or parapharmaceutical category rather than as a registered medicine. Certificate details in circulation could not be verified: the same number appears against different products on the manufacturer's own materials, and they follow a format from a registration regime since superseded. |
United States FDA | Unapproved / investigational as of 11 Aug 2026 | No marketing authorisation. The FDA has not evaluated this compound — that is an absence of any opinion, not a negative finding. |
European Union EMA | Unapproved / investigational as of 11 Aug 2026 | No marketing authorisation. |
India CDSCO | Unapproved / investigational as of 11 Aug 2026 | Not approved for human use. A first-time synthetically manufactured peptide falls under the new-drug pathway. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
No community use documented for this compound yet. Absence here means our editorial team has not reviewed and verified a pattern — not that none exists.
Active clinical trials
No registered trials currently tracked for Testagen.
What remains unknown
The questions that would change our assessment if they were answered.
- Can any of the central findings be replicated by a group with no connection to the originating institute?
- Does a peptide this short reach the nucleus intact in a human?
- Is tissue specificity demonstrated, or inferred from the tissue each peptide was derived from?
References
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created. All registration certificate numbers and all trial figures excluded as unverifiable. Graded on absence of independent replication, not on country of origin.
We replaced the generic template human entry (testagen-h1, placeholder reference) and left humanResearch empty: no human study of synthetic Lys-Glu-Asp-Gly could be found, and the only registry match (NCT02733133) is an unrelated testosterone product sold under the Testagen name. We added one preclinical entry, Fedoreyeva, Kireev, Khavinson and Vanyushin 2011 (PMID 22117547). In that paper, fluorescein-labelled testagen reached HeLa cell nuclei, and the unlabelled peptide showed sequence-dependent quenching with DNA oligonucleotides in cell-free assays. It is recorded as work from the originating programme, not as replication. The sequence KEDG was checked against this paper and against the Chita State Medical Academy series and is unchanged. Those abstracts describe the peptide as derived from pituitary cytomedins, not testicular tissue, so the dossier's 'testicular' label currently has no support. The testicular extract (patent RU2302874, PMID 28243903) and the gamma-Glu-Lys dipeptide (RU2324703) are different materials and are not cited under Testagen. The grade stays insufficient. Before approval, the entry was corrected to attribute the Moscow agricultural-biotechnology affiliation only to the first author, to drop a claim that the paper is the primary source for the sequence, and to scope its no-outcome statements to what the abstract reports.
Spotted something wrong? Tell us — we publish corrections.